Poly(ADP-ribose) polymerase 1. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Olaparib CHEMBL521686 |
PARP 1, 2 and 3 inhibitor Inhibitor Small molecule |
✓ Both | 115 |
| Niraparib CHEMBL1094636 |
Poly [ADP-ribose] polymerase-1 inhibitor Inhibitor Small molecule |
✓ Both | 37 |
| Saruparib CHEMBL5095220 |
Inhibits PARP1 Primary target Small molecule |
Guide to Pharmacology only | 12 |
| Talazoparib CHEMBL3137320 |
Poly [ADP-ribose] polymerase-1 inhibitor Inhibitor Small molecule |
✓ Both | 12 |
| Rucaparib CHEMBL1173055 |
PARP 1, 2 and 3 inhibitor Inhibitor Small molecule |
✓ Both | 4 |
| Pamiparib CHEMBL4112930 |
Poly [ADP-ribose] polymerase-1 inhibitor Inhibitor Small molecule |
✓ Both | 3 |
| Veliparib CHEMBL506871 |
PARP 1, 2 and 3 inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Senaparib CHEMBL4802152 |
Poly [ADP-ribose] polymerase-1 inhibitor Inhibitor Small molecule |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Breast cancer | 7 | Phase 3 |
| Prostate cancer | 7 | Phase 3 |
| Cancer | 6 | Phase 3 |
| Fallopian tube cancer | 6 | Phase 3 |
| Malignant epithelial tumor of ovary | 5 | Phase 3 |
| Primary peritoneal carcinoma | 5 | Phase 3 |
| Small cell lung carcinoma | 5 | Phase 3 |
| Endometrial cancer | 4 | Phase 3 |
| Fallopian tube carcinoma | 4 | Phase 3 |
| Non-small cell lung carcinoma | 4 | Phase 3 |
| Ovarian cancer | 4 | Phase 3 |
| Ovarian carcinoma | 4 | Phase 3 |
| Gastric cancer | 3 | Phase 3 |
| Malignant pancreatic neoplasm | 3 | Phase 3 |
| Ovarian endometrioid adenocarcinoma | 3 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
